Two microbiological relapses in a patient with lepromatous leprosy.
A lepromatous patient treated with dapsone in the pre-MDT era to the point of smear negativity (> 6 years), relapsed 5 years after stopping treatment. He was then put on WHO-MDT for multibacillary (MB) leprosy, and was treated again; he had negative slit skin smears (3 years). He again presented with a relapse of leprosy 17 years after stopping treatment, and this time he presented with borderline leprosy in reaction.
Chakma
J K
JK
National JALMA Institute for Leprosy and Other Mycobacterial Diseases, ICMR, Tajganj, Agra 282 001, India.
Girdhar
A
A
Natrajan
M
M
Kumar
A
A
Girdhar
B K
BK
D003622:Dapsone / Q000008:administration & dosage / Q000627:therapeutic use; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D006801:Humans; D007917:Leprostatic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D015439:Leprosy, Borderline / Q000175:diagnosis / Q000188:drug therapy / Q000382:microbiology / Q000517:prevention & control; D015440:Leprosy, Lepromatous / Q000188:drug therapy / Q000382:microbiology / Q000517:prevention & control; D008297:Male; D008875:Middle Aged; D009166:Mycobacterium leprae / Q000187:drug effects* / Q000302:isolation & purification; D012008:Recurrence; D016896:Treatment Outcome
D007917:Leprostatic Agents; D003622:Dapsone